Sildenafil (Viagra), the first approved and widely used oral drug for the treatment of erectile dysfunction, was occasionally associated with life-threatening ventricular arrhythmias in patients. Since inward rectifier potassium current (IK1) may considerably contribute to this arrhythmogenesis, we investigated the effect of sildenafil on the human Kir2.1 and Kir2.2, the prevailing subunits forming the ventricular IK1 channels. Experiments were performed by the whole-cell patch clamp technique at 37°C using Chinese hamster ovary cells transiently expressing the human Kir2.1 and Kir2.2 channels. Changes of both the inward and outward current components (at -110 and -50 mV, respectively) were tested to be able to consider the physiological relevance of the sildenafil effect (changes at -110 and -50 mV did not significantly differ, results at -50 mV are listed below). A significant Kir2.1 inhibition was observed at all applied sildenafil concentrations (16.1% ± 3.7%, 20.0% ± 2.6%, and 15.0% ± 3.0% at 0.1, 1, and 10 μM, respectively). The inhibitory effect of 0.1 μM sildenafil was potentiated by the presence of a low concentration of Ba2+ (0.1 μM) which induced only a slight Kir2.1 inhibition by 5.95% ± 0.75% alone (the combined effect was 35.5% ± 3.4%). The subtherapeutic and therapeutic sildenafil concentrations (0.1 and 1 μM) caused a dual effect on Kir2.2 channels whereas a significant Kir2.2 activation was observed at the supratherapeutic sildenafil concentration (10 μM: 34.1% ± 5.6%). All effects were fully reversible. This is the first study demonstrating that sildenafil at clinically relevant concentrations inhibits both the inward and outward current components of the main human ventricular IK1 subunit Kir2.1. This inhibitory effect was significantly potentiated by a low concentration of environmental contaminant Ba2+ in agreement with recently reported data on rat ventricular IK1 which additionally showed a significant repolarization delay. Considering the similar subunit composition of the human and rat ventricular IK1 channels, the observed effects might contribute to sildenafil-associated arrhythmogenesis in clinical practice.

Department of Molecular Pharmacy Faculty of Pharmacy Masaryk University Brno Czech Republic

Department of Physiology Faculty of Medicine Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc23003010

003      

CZ-PrNML

005      

20230518100657.0

007      

ta

008      

230413s2023 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3389/fphar.2023.1136272 $2 doi

035    __

$a (PubMed)36817146

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Iijima, Akimasa $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

245    10

$a Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations: Inhibition potentiated by low Ba2 / $c A. Iijima, O. Švecová, J. Hošek, R. Kula, M. Bébarová

520    9_

$a Sildenafil (Viagra), the first approved and widely used oral drug for the treatment of erectile dysfunction, was occasionally associated with life-threatening ventricular arrhythmias in patients. Since inward rectifier potassium current (IK1) may considerably contribute to this arrhythmogenesis, we investigated the effect of sildenafil on the human Kir2.1 and Kir2.2, the prevailing subunits forming the ventricular IK1 channels. Experiments were performed by the whole-cell patch clamp technique at 37°C using Chinese hamster ovary cells transiently expressing the human Kir2.1 and Kir2.2 channels. Changes of both the inward and outward current components (at -110 and -50 mV, respectively) were tested to be able to consider the physiological relevance of the sildenafil effect (changes at -110 and -50 mV did not significantly differ, results at -50 mV are listed below). A significant Kir2.1 inhibition was observed at all applied sildenafil concentrations (16.1% ± 3.7%, 20.0% ± 2.6%, and 15.0% ± 3.0% at 0.1, 1, and 10 μM, respectively). The inhibitory effect of 0.1 μM sildenafil was potentiated by the presence of a low concentration of Ba2+ (0.1 μM) which induced only a slight Kir2.1 inhibition by 5.95% ± 0.75% alone (the combined effect was 35.5% ± 3.4%). The subtherapeutic and therapeutic sildenafil concentrations (0.1 and 1 μM) caused a dual effect on Kir2.2 channels whereas a significant Kir2.2 activation was observed at the supratherapeutic sildenafil concentration (10 μM: 34.1% ± 5.6%). All effects were fully reversible. This is the first study demonstrating that sildenafil at clinically relevant concentrations inhibits both the inward and outward current components of the main human ventricular IK1 subunit Kir2.1. This inhibitory effect was significantly potentiated by a low concentration of environmental contaminant Ba2+ in agreement with recently reported data on rat ventricular IK1 which additionally showed a significant repolarization delay. Considering the similar subunit composition of the human and rat ventricular IK1 channels, the observed effects might contribute to sildenafil-associated arrhythmogenesis in clinical practice.

590    __

$a NEINDEXOVÁNO

655    _2

$a časopisecké články $7 D016428

700    1_

$a Švecová, Olga $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0301708

700    1_

$a Hošek, Jan $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic

700    1_

$a Kula, Roman $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

700    1_

$a Bébarová, Markéta $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

773    0_

$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 14, č. - (2023), s. 1136272

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36817146 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230413 $b ABA008

991    __

$a 20230518100651 $b ABA008

999    __

$a ok $b bmc $g 1922742 $s 1189217

BAS    __

$a 3

BAS    __

$a PreBMC-PubMed-not-MEDLINE

BMC    __

$a 2023 $b 14 $c - $d 1136272 $e 20230202 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597

LZP    __

$a Pubmed-20230413